Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2025 16:40 ET | Source: Alvotech

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine...
November 10, 2025 23:49 ET | Source: Don Gray

Don Gray announces Acquisition of Shares of Lotus Creek Exploration Inc.

SCOTTSDALE, Ariz., Nov. 10, 2025 (GLOBE NEWSWIRE) -- This press release is being issued in accordance with the early warning requirements of applicable Canadian securities laws. On November 10,...
November 10, 2025 07:00 ET | Source: Lotus Technology Inc.

Lotus Technology to Report Unaudited Third Quarter 2025 Financial Results on November 24, 2025

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus" or the "Company") (Nasdaq: LOT), a leading global intelligent and luxury mobility provider, today announced that it will...
November 10, 2025 04:00 ET | Source: Alvotech

Alvotech vinnur sigur í mikilvægu dómsmáli um framleiðslu og markaðssetningu AVT06 hliðstæðunnar við Eylea (aflibercept)

Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að dómstóll í Bretlandi hafi hafnað lögbannskröfu Regeneron Pharmaceuticals og Bayer sem beindist að Alvotech og þjónustuaðila félagsins í Bretlandi....
November 10, 2025 04:00 ET | Source: Alvotech

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

REYKJAVIK, ICELAND (November 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced...
November 10, 2025 04:00 ET | Source: Alvotech

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
November 06, 2025 09:07 ET | Source: Alvotech

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

REYKJAVIK, Iceland and LONDON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
November 06, 2025 09:00 ET | Source: Alvotech

Alvotech og Advanz Pharma fá markaðsleyfi í Bretlandi fyrir Gobivaz, hliðstæðu við Simponi (golimumab)

REYKJAVÍK OG LONDON (6. OKTÓBER 2025) - Breska lyfjastofnunin (MHRA) hefur veitt markaðsleyfi fyrir allar útgáfur Gobivaz, hliðstæðu Alvotech við líftæknilyfið Simponi (golimumab). Samstarfsaðili...
November 06, 2025 09:00 ET | Source: Alvotech

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide...
November 06, 2025 07:00 ET | Source: Avalo Therapeutics

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026Appointed Kevin Lind to Board of DirectorsExpanded leadership team...